Olfactomics Surgery SIGNED

Project "Olfactomics Surgery" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Currently, cancer tumor removal operation is based on preoperative imaging and postoperative pathological examination. There is a strong global trend towards more tissue-sparing and minimally invasive surgery. If all cancer is not removed in the operation, a reoperation is needed, leading to additional costs, impaired cost-effectiveness and impaired quality of life of the patient. The rate of incomplete removal of a tumor ranges from 10-60%. The breakthrough innovative Olfactomics device allows the surgeon to analyze the operated tissue in real-time during cancer surgery leading to optimal tissue removal without compromising the workflow of the operation and facilitating the use of existing instrumentation. The solution is based on noninvasive, real-time analysis of surgical smoke. The reduced reoperation rate results in significant benefits for the patient, surgeon, hospital and society. The market potential is high. Easily reachable market for the breast cancer surgery is 850M€ and market for other applicable specialties (such as prostate cancer, skin cancer, and intestinal surgery) is over 2,000M€. Olfactomics Oy is a Finnish university-based spinoff company founded in 2015 to commercialize the results of over 10 years of clinical and technical research. The team consists of 13 specialists in surgery, medical technology, software, data analysis, financials and law. The team has excellent connections in the international healthcare industry and sensor technology industry. The technology is currently at TRL 7. The first commercial product for research use will be launched in 2019. This project will focus on scale-up to Olfactomics medical device on breast cancer surgery. The impacts by 2027 include: 3,000 Olfactomics devices sold; 300,000 Olfactomics breast cancer surgeries performed, 70,000 women saved from reoperation, 900M€ costs savings in health care, 100M€ revenue and 200 direct workplaces generated. Scale-up to several surgical areas will follow.